US11007194B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11007194-B2 |
| Application number | US-201214355903-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2012 |
| Priority date | Nov 11, 2011 |
| Publication date | May 18, 2021 |
| Grant date | May 18, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.
Opening claim text (preview).
We claim: 1. A method of treating a proliferative disease in a subject in need thereof, wherein the proliferative disease is melanoma or colorectal cancer, and wherein the proliferative disease is characterized by a mutation in BRAF kinase, wherein the method comprises suppressing resistance to treatment with a BRAF inhibitor of the Formula II by administering the BRAF inhibitor of Formula II to the subject on an intermittent dosing schedule, wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 1, 2, 3, 4, 5, or 6 weeks followed by a period of 1, 2, 3, 4, 5, or 6 weeks without treatment. 2. A method of claim 1 wherein the BRAF mutation is a V600 mutation. 3. A method of claim 1 wherein the proliferative disease is melanoma which is characterized by a V600 mutation or colorectal cancer characterized by a V600 mutation. 4. A method of claim 1 wherein the proliferative disease is melanoma which is characterized by BRAFV600E or colorectal cancer characterized by BRAFV600E. 5. A method of claim 1 wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of two weeks without treatment and repeating the cycle while the patient is treated with the BRAF inhibitor or until resistance emerges. 6. A method of claim 1 wherein the intermittent dosing schedule improves a therapeutic effect in tumor cells already resistant to treatment with the BRAF kinase inhibitor of Formula II. 7. The method of claim 1 , wherein the proliferative disease is a tumor. 8. The method of claim 7 , wherein said tumor is melanoma which is characterized by a V600 mutation. 9. The method of claim 8 , wherein said tumor is melanoma which is characterized by a V600E mutation. 10. The method of claim 8 , wherein the BRAF inhibitor of Fomula II is administered once daily during the period of administration of the BRAF inhibitor of Formula II. 11. The method of claim 9 , wherein the BRAF inhibitor of Formula II is administered once daily during the period of administration of the BRAF inhibitor of Formula II. 12. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor of Formula II for a period of 4 weeks followed by a period of 2 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld, and repeating the cycle while the patient is treated with the BRAF inhibitor of Formula II. 13. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 1 week followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 14. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 2 weeks followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 15. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 2 weeks followed by a period of 2 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 16. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 3 weeks followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 17. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 3 weeks followed by a period of 2 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 18. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 3 weeks followed by a period of 3 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 19. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 20. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of 3 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 21. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of 4 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 22. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 5 weeks followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 23. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 5 weeks followed by a period of 2 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 24. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 5 weeks followed by a period of 3 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 25. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 5 weeks followed by a period of 4 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 26. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 5 weeks followed by a period of 5 weeks wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 27. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 6 weeks followed by a period of 1 week wherein treatment with the BRAF inhibitor of Formula II is withheld and repeating the cycle while the patient is treated with the BRAF inhibitor. 28. The method of claim 11 , wherein the intermittent dosing schedule comprises administering the BRAF inhibitor for a
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
not condensed and containing further heterocyclic rings · CPC title
Antineoplastic agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.